Seltz Judith C
Known title: EVP, CHROCIK: 0001791228
Associated companies
Transaction History
| LH | ▼ Sell | Tax Withholding | 1,164 | $262K | 3/30/2023 | View on chart |
| LH | ▲ Buy | Grant | 3,381 | $0 | 3/30/2023 | View on chart |
| LH | ▼ Sell | Tax Withholding | 69 | $17K | 2/13/2023 | View on chart |
| LH | ▲ Buy | Option Exercise | 236 | — | 2/11/2023 | View on chart |
| LH | ▼ Sell | Tax Withholding | 84 | $21K | 2/6/2023 | View on chart |
| LH | ▲ Buy | Option Exercise | 280 | — | 2/4/2023 | View on chart |
| LH | ▼ Sell | Tax Withholding | 77 | $20K | 2/2/2023 | View on chart |
| LH | ▲ Buy | Option Exercise | 220 | — | 2/2/2023 | View on chart |
| LH | ▼ Sell | Tax Withholding | 85 | $24K | 2/4/2022 | View on chart |
| LH | ▲ Buy | Option Exercise | 280 | — | 2/4/2022 | View on chart |
| LH | ▼ Sell | Tax Withholding | 76 | $21K | 2/2/2022 | View on chart |
| LH | ▲ Buy | Option Exercise | 220 | — | 2/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Labcorp to Acquire OPKO Health's BioReference Assets for $722M
Labcorp has agreed to acquire select assets from OPKO Health's BioReference division for $722 million. This move expands Labcorp's capabilities in the diagnostics sector, a key area for the company's growth. The stock is currently trading near its 52-week high, reflecting investor interest in this strategic acquisition.
Labcorp to Acquire OPKO Health's BioReference Assets for $722M. Labcorp has agreed to acquire select assets from OPKO Health's BioReference division for $722 million. This move expands Labcorp's capabilities in the diagnostics sector, a key area for the company's growth. The stock is currently trading near its 52-week high, reflecting investor interest in this strategic acquisition.